NEW YORK (GenomeWeb) — BGI Europe has inked an exclusive technology transfer deal with Spain's NIM Genetics for BGI Europe's non-invasive prenatal testing technology.

The deal allows NIM to begin offering BGI Europe's NIPT in Spain. The test, called TrisoNIM Advance and marketed as Nifty in other parts of Europe, detects the risk of genetic conditions such as Down syndrome from as early as 10 weeks into the pregnancy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.